No Placebo-Only Group

Pivotal Trial

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Vaccine Therapy for Patients With Stage III Melanoma

Vaccine Therapy for Stage III Melanoma

This study is evaluating whether a vaccine can prevent or slow the recurrence of melanoma.

All visible signs of my disease have been surgically removed.

I am not on medications or therapies that weaken my immune system.

CancerVax™ Vaccine

This is a Phase III study in patients with melanoma that has spread to the lymph nodes and/or a distant organ, and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Vaccine Therapy for Patients With Stage IV Melanoma

Cancer Vaccine for Melanoma

All visible signs of my disease were removed with surgery.

I am not on any treatments that weaken my immune system.

All Individual Drugs Already Approved

Approved for 10 Other Conditions

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using triptorelin, exemestane, and tamoxifen may fight breast cancer by blocking the use of estrogen. It is not yet known whether giving triptorelin together with exemestane is more effective than triptorelin and tamoxifen in treating hormone-responsive breast cancer.

PURPOSE: This randomized phase III trial is studying triptorelin and exemestane to see how well they work compared to triptorelin and tamoxifen in treating premenopausal women with hormone-responsive breast cancer.

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Hormone Therapy for Breast Cancer

This study is evaluating whether a combination of hormones is more effective than a single hormone in treating breast cancer.

I don't have any chronic diseases that would interfere with long-term treatment.

I haven't had any cancer except for skin cancer in the last 5 years.

My breast cancer cannot be removed by surgery and has spread to nearby areas.

I have not had chemotherapy before or after surgery.

I haven't had any cancer except certain skin cancers or non-spreading breast cancer in the last 5 years.

My estrogen levels are considered premenopausal after surgery.

I have never had a blood clot or if I did, my doctor says it's okay.

My breast cancer diagnosis was confirmed through tissue examination.

My cancer has not spread to distant parts of my body.

I have had breast cancer in either the same or the opposite breast before.

I do not have liver disease that would interfere with long-term monitoring.

I do not have kidney disease that would interfere with long-term monitoring.

I am not taking any estrogen, progesterone, or androgen treatments.

I am not taking any other aromatase inhibitors.

I don't have any lung diseases that would interfere with long-term monitoring.

I am fertile and not using birth control methods that don't involve hormones.

I haven't had hormone therapy for breast cancer since diagnosis.

I have never had radiation therapy for ovarian cancer.

I am not currently taking bisphosphonates, or I meet the specific criteria for their use.

I haven't used tamoxifen, SERMs, or hormone therapy for over a year before my breast cancer diagnosis.

I am not currently on any oral or patch-based hormone treatments.

I have not had both of my ovaries removed.

I do not have any detectable cancer in the lymph nodes under my arm.

I am a woman who has not gone through menopause.

I have had surgery to remove lymph nodes under my arm or a biopsy that was negative.

I am not using any hormonal contraceptives.

My cancer is only in my breast and nearby lymph nodes.

My cancer was entirely removed by surgery.

I don't have heart disease that would interfere with long-term monitoring.

I have had surgery or radiation on the lymph nodes under my arm due to cancer.

My cancer is positive for estrogen or progesterone.

I have had a condition where my lymphocytes grow abnormally.

I have never had invasive breast cancer before.

Exemestane

Tamoxifen

Triptorelin

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This randomized phase III trial is comparing two different combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III non-seminomatous germ cell tumors.

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Chemotherapy for Germ Cell Tumors

This study is evaluating whether a combination of drugs is more effective than a single drug in treating non-seminomatous germ cell tumors.

I have a type of testicular cancer with high HCG or AFP levels, or it has spread.

My cancer is in an advanced stage, affecting the area around my heart or other organs.

I have had cancer before, but it was not skin cancer.

Bleomycin Sulfate

Cisplatin

Etoposide

Ifosfamide

Oxaliplatin

Paclitaxel

This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Vorinostat + Temozolomide for Brain Cancer

This study is evaluating the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas.

I have a history of cancer or blood cell disorders.

It has been at least 3 weeks since my last radiation therapy.

I haven't had any cancer except for basal or squamous cell skin cancer in the last 5 years.

My condition worsened despite taking temozolomide.

I do not have any active infections or serious illnesses.

I have a condition that affects how drugs are broken down in my body.

I am HIV positive and on antiretroviral therapy.

My hemoglobin level is at least 10 g/dL, transfusions included.

My steroid medication dose has been stable.

I have been diagnosed with a specific type of brain tumor.

I can care for myself but may need occasional help.

My low-grade brain tumor was later found to be cancerous.

Temozolomide

Vorinostat

This partially randomized phase I/II trial studies the side effects and the best dose of cediranib maleate and olaparib and to see how well they work compared to olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has returned after a period of improvement (recurrent). Cediranib maleate may help keep cancer cells from growing by affecting their blood supply. Olaparib may stop cancer cells from growing abnormally. The combination of cediranib maleate and olaparib may be safe, tolerable and/or effective in treating patients with recurrent ovarian, fallopian tube, or peritoneal cancer or recurrent triple-negative breast cancer.

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Cediranib + Olaparib for Ovarian and Breast Cancer

This study is evaluating whether a combination of cediranib maleate and olaparib is better than olaparib alone in treating patients with ovarian, fallopian tube, peritoneal, or triple-negative breast cancer that has

You have had allergic reactions to similar drugs as cediranib maleate or olaparib.

Participants in the Phase II part of the trial must have a way to measure their disease according to specific guidelines.

Your total bilirubin level is within 1.5 times the normal limit at the hospital.

My breast cancer returned after treatments with Adriamycin and taxane.

Side effects from my previous cancer treatment are mild or gone, except for hair loss.

I had skin, breast, or cervical cancer but it was treated early and did not spread.

Your AST and ALT levels in your blood are not more than 2.5 times the normal limit.

My kidney function is within the normal range.

I am at high risk for heart problems and need close heart monitoring.

My tests do not show signs of MDS or AML.

I do not have untreated brain metastases or symptoms from brain or spinal cord tumors.

I do not have HIV due to potential drug interactions.

My cancer can be measured by scans or I have high CA125 levels.

I agree to use birth control during and 3 months after the study.

My ovarian cancer treatment included platinum-based chemotherapy.

I have not taken anti-angiogenic drugs for my recurrent or metastatic cancer.

I can check and record my blood pressure every day.

I haven't had chemotherapy or radiotherapy in the last 3 weeks, or 6 weeks for specific drugs, and have recovered from any side effects.

I do not use herbal products or folk remedies.

I am not pregnant, as the treatment could harm my unborn baby.

My cancer is measurable or my CA125 levels are high.

Your white blood cell count is not too low.

You are expected to live for at least 6 more months.

I am fully active or able to carry out light work.

I can take pills and don't have stomach issues that affect medication absorption.

I am not taking strong medication that affects liver enzyme CYP3A4.

You have low levels of protein in your urine on two separate tests taken at least a week apart, or a specific ratio of protein to creatinine in your urine.

Your troponin T or I levels are within the normal range at the hospital where you are being treated.

Your blood clotting tests (INR, aPTT) are within a certain range, unless you have a confirmed Lupus anticoagulant.

You have enough platelets in your blood (at least 100,000 per microliter).

Your hemoglobin level is higher than 9 grams per deciliter.

I have been diagnosed with a specific type of ovarian, fallopian tube, peritoneal, or triple-negative breast cancer.

I have not taken PARP inhibitors for my recurrent or metastatic cancer.

To put it simply, this criterion means that the researchers are looking for patients who do not have any of the conditions listed.

Cediranib Maleate

Olaparib

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Pertuzumab + Chemotherapy + Trastuzumab for Breast Cancer

This study is evaluating whether pertuzumab can be safely added to chemotherapy and trastuzumab in people with breast cancer.

I haven't had cancer other than specific skin cancers or early-stage cervical or colon cancer in the last 5 years.

You are currently receiving experimental treatment for cancer in another research study.

You are allergic to any of the study medications or their ingredients.

I am fully active and can carry on all my pre-disease activities without restriction.

I have a serious heart or blood vessel condition.

I started chemotherapy within 8 weeks after my breast cancer surgery.

I know my cancer's hormone receptor status.

My cancer has not spread to the lymph nodes.

I agree to use effective birth control during and for 7 months after the study.

Your heart's pumping ability, measured by a special heart test, is at least 55%.

My cancer is classified as T4, indicating it is advanced.

I have had chemotherapy or radiotherapy for cancer before.

I have previously used anti-HER2 or other biologic/immunotherapy for cancer.

I have had breast cancer before, on either or both sides.

My breast cancer is HER2-positive, hasn't spread, and was surgically removed.

I do not have severe lung problems that could affect my treatment.

Your recent lab tests show abnormal results.

5-Fluorouracil

Carboplatin

Cyclophosphamide

Docetaxel

Doxorubicin

Epirubicin

Pertuzumab

Trastuzumab

This is a prospective, multicentre, randomized clinical trial comparing two different neo-adjuvant radiation-based strategies prior to intended surgery for locally advanced adenocarcinoma of the rectum.

This trial may establish the investigational therapy to be superior to, or at least not inferior to conventional treatment.

Resource-Sparing Curative Treatment for Rectal Cancer

Radiotherapy for Colorectal Cancer

This study is evaluating whether a new treatment for rectal cancer is better than the standard treatment.

My rectal cancer is advanced or has spread to nearby tissues.

My initial cancer treatment was aimed at curing me.

I am mostly self-sufficient and can undertake treatment.

My hemoglobin level is below 8.0 without needing a blood transfusion.

I can attend all necessary follow-up appointments.

My cancer has spread beyond the pelvic area.

My cancer is located entirely in the sigmoid colon.

My current medications won't interfere with the trial's chemotherapy.

Radiotherapy

Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy).

Following chemoimmunotherapy patients receive radiation therapy if they have residues which may be active tumour. However at the end of chemoimmunotherapy the majority of patients show tissue scarring that is not necessarily active tumor. In recent years, PET/CT has proved to be a good tool to accurately identify active tumor from scar tissue in patients treated for mediastinal lymphoma.The purpose of this trial is to test whether radiation therapy is really necessary in patients where PET/CT has shown that the tumor is no longer active. Therefore we will compare radiation treatment with careful observation.

Patients that at the end of conventional treatment of chemoimmunotherapy have a negative PET/CT (i.e., without residues suspected to contain active tumor), will randomly assigned to two different treatment groups: one treatment group will receive the radiation treatment, and the other treatment group will receive careful observation.

The trial is planned according to a non-inferiority design aimed at demonstrating that progression free survival after the experimental treatment (observation) is not worse than after the standard comparator (mediastinal irradiation.Participation in this study could spare patients with complete remission at the end of chemo immunotherapy (PET/CT negative) radiation therapy that may be unnecessary.

Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma

Radiation Therapy vs Observation for B-Cell Lymphoma

This study is evaluating whether radiation therapy is really necessary in patients where PET/CT has shown that the tumor is no longer active.

I am considered healthy enough to undergo chemotherapy and radiotherapy aimed at curing my condition.

I am receiving Rituximab with anthracycline chemotherapy but not stem cell support.

My cancer has not spread outside my chest, spleen, or bone marrow.

I have a type of lymphoma that has not been treated yet.

My cancer diagnosis was confirmed with specific tests and I have a major tumor in the front of my chest area.

I have received at least 6 treatments with Rituximab.

I am willing to use birth control during the study.

I haven't had cancer, except for specific skin cancers or cervical pre-cancer, in the last 5 years.

I have had serious heart problems like heart failure or a heart attack in the last year.

3D-Conformal Radiotherapy (3D-CRT)

observation

Rituximab

This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Romidepsin for Cancer and Chronic Lymphocytic Leukemia with Liver Dysfunction

This study is evaluating the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.

I do not have prostate, renal cell, neuroendocrine, lung, colorectal cancers, soft tissue sarcomas, glioma, or thyroid cancer.

I have previously been treated with romidepsin.

You need to have a certain level of red blood cells, white blood cells, platelets, and a substance called creatinine in your blood.

I haven't had major surgery or antibody therapies recently.

I have relapsed or refractory PTCL or CTCL without time restrictions on my last treatment.

I am not taking any medications that affect heart rhythm.

I do not have any severe illnesses or social situations that would stop me from following the study's requirements.

My cancer does not respond to standard treatments anymore.

I have a liver tumor, high alpha-fetoprotein levels, and hepatitis, indicating liver cancer.

I do not have prostate, renal, neuroendocrine, lung, colorectal cancers, soft tissue sarcomas, glioma, or thyroid cancer.

I have a specific type of cancer and meet certain conditions for the study.

My liver isn't working normally, but I can still join the study.

National Cancer Institute Clinical Trials 2022

Trials at this site

Cediranib + Olaparib for Ovarian and Breast Cancer

Is this your site?

Is this your site?